Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFFERIN vs SODIUM TETRADECYL SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
FDA-approved for the topical treatment of acne vulgaris in patients aged 12 and older. Off-label uses include treatment of photodamage, keratosis pilaris, and actinic keratoses.
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins,Treatment of small varicose veins (off-label for larger varicose veins)
Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.
1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.
Terminal elimination half-life is approximately 14–22 hours; steady-state is achieved within 3–5 days.
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Adapalene is minimally metabolized in the skin; systemic absorption is low. Any absorbed drug is primarily metabolized in the liver via cytochrome P450 enzymes, likely CYP2C9 and CYP3A4, and excreted in bile as metabolites.
Not extensively metabolized; primarily eliminated unchanged by the kidneys.
Primarily biliary/fecal (>95%) as unchanged drug and metabolites; renal excretion is negligible.
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Highly protein-bound (>99%), mainly to plasma albumin and lipoproteins.
Approximately 50% bound to plasma proteins (albumin and globulins).
Large volume of distribution (~14–16 L/kg), indicating extensive tissue binding and distribution.
0.2–0.3 L/kg, indicating distribution primarily within extracellular fluid and plasma volume.
Topical absorption is minimal (<5% of applied dose); systemic bioavailability is negligible.
Intravenous: 100% (direct intravascular administration). Oral: negligible due to extensive degradation and poor absorption.
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
Use with caution in Child-Pugh class C; no specific dose adjustment defined.
Approved for acne vulgaris in patients aged 12 years and older: apply 0.1% gel or cream once daily. Safety and efficacy in children under 12 not established.
0.1-0.3 m L of 1% solution per injection, repeated as needed; maximum 5 m L per session.
No specific dose adjustment; use with caution due to increased risk of skin irritation and dryness in elderly skin.
No specific adjustment; use lowest effective dose due to potential increased sensitivity.
None.
None.
Avoid application to cuts, abrasions, eczematous, or sunburned skin.,Avoid excessive exposure to sunlight and UV light; use sunscreen.,Possible local skin reactions: erythema, scaling, dryness, burning, pruritus; dose reduction or interruption may be necessary.,Use caution in patients with eczema.,Not for oral or ophthalmic use.
Anaphylactic shock and severe allergic reactions have been reported.,Intra-arterial injection can cause severe necrosis or ischemia.,Extravasation may cause pain and tissue necrosis.,Use caution in patients with underlying arterial disease or hypercoagulable states.,Thromboembolic events including deep vein thrombosis and pulmonary embolism have been reported.
Hypersensitivity to adapalene or any component of the formulation. Not for use in patients with known sensitivity to retinoids.
Known hypersensitivity to sodium tetradecyl sulfate or any component of the formulation,Acute thromboembolic disease,Severe peripheral arterial disease,Valvular incompetence of the deep venous system,Uncontrolled systemic disease (e.g., diabetes, thyroid disorders),Local infection or inflammation at the injection site
No significant food interactions. However, high-fat meals may slightly increase systemic absorption; unlikely to be clinically relevant.
No specific food interactions have been reported with sodium tetradecyl sulfate. However, maintaining adequate hydration is recommended. Avoid excessive alcohol intake, as it may exacerbate venous insufficiency.
Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/third trimester: limited data, avoid use. No adequate human studies.
Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack of safety data, especially in the first trimester. Theoretical risk of placental transfer is low due to high molecular weight and local administration. No reported fetal anomalies.
Not recommended. Excretion into human milk unknown; low systemic absorption likely but risk to infant cannot be excluded. M/P ratio not established.
No data on excretion into human milk. M/P ratio unknown. Due to local administration and rapid metabolism, systemic exposure is minimal. Caution advised; consider discontinuing breastfeeding or avoiding use in lactating women.
Discontinue use. No dosage adjustment studies; topical application is contraindicated regardless of pharmacokinetic changes.
No specific dose adjustments recommended. Use only if clearly needed, with smallest effective volume and concentration. Physiological changes in pregnancy (increased plasma volume, altered coagulation) may affect response but no pharmacokinetic data exist.
Use a pea-sized amount for entire face to avoid irritation. Initiate with lower concentration (0.1% gel) for sensitive skin. Combination with benzoyl peroxide or topical antibiotics may enhance efficacy. Sunscreen is mandatory due to photosensitization. Do not apply to broken, eczematous, or sunburned skin.
Sodium tetradecyl sulfate is a sclerosing agent used for the treatment of varicose veins and telangiectasias. It works by causing endothelial damage and subsequent fibrosis of the vein. Use with caution in patients with a history of deep vein thrombosis, pulmonary embolism, or hypercoagulable states. Allergic reactions, including anaphylaxis, have been reported; a test dose is recommended. Avoid extravasation as it may cause tissue necrosis. Compression stockings should be applied post-injection to enhance efficacy and reduce complications.
Apply a thin layer once daily at bedtime to clean, dry skin.,Avoid excessive washing or using abrasive cleansers.,Use oil-free, non-comedogenic moisturizers and cosmetics.,Expect initial worsening of acne (retinoid reaction) which resolves in 4-6 weeks.,Sun protection (SPF 30+) and protective clothing are essential daily.,Minimize exposure to extreme wind or cold.,If pregnant, planning pregnancy, or breastfeeding, consult physician before use.,Keep away from eyes, mouth, nasal angles, and mucous membranes.
This medication is injected directly into your varicose veins to cause them to scar and close.,You may experience temporary bruising, pain, or redness at the injection site.,It is normal for the treated veins to feel hard and lumpy for a few weeks after treatment.,You will need to wear compression stockings for several days to weeks as directed by your healthcare provider.,Avoid sun exposure to the treated area until bruising resolves to reduce the risk of hyperpigmentation.,Seek immediate medical attention if you experience signs of an allergic reaction, chest pain, or difficulty breathing.,Do not discontinue prescribed blood thinners unless instructed by your doctor, as the risk of bleeding may be increased.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFFERIN vs SODIUM TETRADECYL SULFATE, answered by our medical review team.
DIFFERIN is a Topical Retinoid that works by Adapalene is a retinoid-like compound that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression and normalizing differentiation and proliferation of follicular epithelial cells, reducing comedogenesis and inflammation.. SODIUM TETRADECYL SULFATE is a Sclerosing Agent that works by Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFFERIN and SODIUM TETRADECYL SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFFERIN is: Apply a thin layer of 0.1% gel or cream to affected areas once daily in the evening.. The standard adult dose of SODIUM TETRADECYL SULFATE is: 1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIFFERIN and SODIUM TETRADECYL SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIFFERIN is classified as Category C. Pregnancy Category C. Animal studies show teratogenicity at high oral doses; topical exposure has minimal systemic absorption. First trimester: risk cannot be ruled out. Second/thi. SODIUM TETRADECYL SULFATE is classified as Category C. Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.